RGEN Repligen Corporation

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

Repligen stock has delivered a strong 1 year gain, yet the broader valuation checks and recent history raise questions about how much upside is left. The intrinsic value estimate from a Discounted Cash Flow (DCF) view is close to the current share price, while market-based multiples lean more expensive. Over 5 years, Repligen shares have declined about 42%, which points to a difficult longer term journey despite a healthier recent rebound. The valuation story now hinges on whether Repligen...

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

Repligen stock has delivered a strong 45.1% one year return, yet the valuation signals are mixed, with the Discounted Cash Flow (DCF) estimate pointing to a price that is close to intrinsic value while market based multiples suggest the shares trade at a premium. That combination leaves Repligen looking less like an obvious bargain and more like a stock where the entry price matters. Repligen’s 45.1% return over the past year highlights that recent shareholders have been rewarded. This...

Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

In July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million versus US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations decreased to US$0.09 from US$0.26. Over the six-month period ended June 30, 2026, Repligen grew revenue to US$398.38 million from US$351.54 million, but net income and EPS declined, highlighting pressure on profitability despite higher...

What Repligen’s Latest Earnings Mean For Shareholders Repligen (RGEN) is in focus after its second quarter 2026 earnings, which showed higher revenue alongside lower net income and earnings per share compared with the same period a year earlier. See our latest analysis for Repligen. Repligen’s recent earnings announcement and past share repurchase activity have come alongside strong momentum in the stock. The 90 day share price return of 41.4% and 1 year total shareholder return of 47.09%...

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.